Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection - read this article along with other careers information, tips and advice on BioSpace
United Kingdom Paul Feuerstadt Eric Shaff Health Science Company Risk Factors In Seres Therapeutics Inc Health Science
Source: biospace.com